（来源：内蒙古日报） 转自：内蒙古日报 本报2月26日讯 （记者 李国萍）记者从内蒙古自治区药监局获悉：为保障群众用药用械安全有效、方便 可及，我区日前印发《内蒙古自治区自助售药机和自动售械机管理规定》（以下简称《规定》），对自 助售药机、自动售械机的设置主体、布局原则、经营范围等方面作出系统性、全流程规范。 《规定》严格界定自助售药机与自动售械机设置主体资格，明确依法取得《药品经营许可证》的零售药 店，可依托自身实体经营店设置自助售药机；依法取得《医疗器械经营许可证》或备案凭证、经营方式 包含零售的医疗器械经营企业，可依托实体门店设置自动售械机，从源头杜绝无资质主体违规开展经营 活动。 针对自助售药机，《规定》明确销售范围仅限乙类非处方药，不含含特殊药品复方制剂，严禁销售处方 药和甲类非处方药；要求设备具备温湿度自动监测调控、远程报警、安全监控、药品追溯、在线药学服 务等功能，药品实行统一采购、统一验收、统一配送、统一管理，全程纳入企业计算机管理系统，实现 采购、销售、库存实时可查。 针对自动售械机，《规定》要求其贮存、销售全流程符合医疗器械经营质量管理规范，仅限销售消费者 可个人自行使用的医疗器械；售械设 ...

中国质量新闻网讯 为推动药品零售行业从"药品销售终端"向"健康服务枢纽"转型，北京市平谷区市场 监管局深入辖区重点药品连锁企业开展现场指导，助力企业完善健康服务体系，更好满足群众多元化的 医药健康需求。 通过专业的检查和指导，企业负责人表示会加快落实，确保执业药师远程审核处方工作"既合规又便 民"，同时做好药品扫码溯源工作，坚决守好药品质量安全关，并严格遵守相关法律规定，维护公平竞 争市场秩序。 下一步，平谷区市场监管局将持续推动药店从"药品销售"向"健康管理"服务升级，着力打造贴合平谷区 群众需求的"健康驿站"，切实助力区域医药健康服务提质增效。（来源：平谷市场监管） 执法人员深入企业药品库房开展现场检查，重点检查库房温湿度监控、避光防潮、分区储存等设施是否 合规，逐项核对设备养护记录与校验凭证，并要求严格保障计算机系统数据与温湿度监测设备的精准可 靠，全面压实药品储存安全责任。同时，为企业服务体系的系统性升级提供专业化指导。 在健全药事服务体系方面，督促企业完善自建的药学服务平台，优化执业药师远程审核处方机制，重点 破解非工作时段、药师轮休期间的服务断点问题，通过平台化手段确保药学服务"在线不断档"。鼓励 ...

Group 1: Market Performance and Trends - The Shanghai Composite Index increased by 25.58% during the Year of the Snake, with the Shenzhen Component Index rising by 38.84%, the ChiNext Index by 58.73%, and the Sci-Tech Innovation Board Index by 64.20% [1] - Institutions predict that after the Spring Festival, the technology sector, particularly AI, is likely to regain its leading position in the market [1] - Historical data shows that the market generally performs well after the Spring Festival, with the Shanghai Composite Index rising in 7 out of the last 10 years during the first five trading days post-holiday [1] Group 2: Industry Developments - The precious metals market has entered a phase of consolidation after experiencing extreme volatility, with prices under pressure due to various macroeconomic factors [2] - Major automotive companies are increasingly investing in the robotics sector, with firms like Tesla and Chery transforming production lines to focus on robot manufacturing [2] - The pharmaceutical retail industry is undergoing a transformation driven by policy support, with a focus on industry consolidation and new business models [3] Group 3: Corporate News - Meituan expects a loss of approximately 23.3 billion to 24.3 billion yuan for the fiscal year 2025, a significant shift from a profit of about 35.8 billion yuan in 2024, primarily due to losses in its core local business segment [6] - Tianfeng Securities is under investigation by the China Securities Regulatory Commission for alleged violations related to financing and information disclosure [7] - Ningde Times, Luoyang Molybdenum, and Laopu Gold are set to be included in the Hong Kong Hang Seng Index, increasing the number of constituent stocks from 88 to 90 [8]

Core Viewpoint - The recent policy initiatives in China's pharmaceutical retail industry aim to promote high-quality development through industry integration, prescription outflow, and commercial insurance, signaling a transition towards a more structured and profitable market environment [1][2][3] Industry Transformation - The policy encourages horizontal mergers and acquisitions among pharmaceutical retail enterprises to enhance industry efficiency and service quality [2] - Local governments are optimizing the business environment, including streamlining the application process for drug operating licenses and allowing the continuation of existing medical insurance qualifications during transitions [2] - The retail pharmaceutical market in China is projected to grow from CNY 2.41 trillion in 2020 to CNY 2.95 trillion by 2024, representing a 22.4% increase [2] Shift to Health Services - The industry is transitioning from traditional drug sales to comprehensive health services, enhancing community health support and emergency supply capabilities [3] - Policies are designed to facilitate the transformation of retail pharmacies into health service hubs, encouraging the expansion of services such as health consultations and chronic disease management [3][6] Corporate Responses - Companies like YaoXingTang are actively responding to the new policies by exploring mergers and acquisitions to enhance their service offerings [4] - LaoBaiXing is focusing on improving the quality of its franchise and alliance businesses while identifying potential acquisition targets to strengthen its market position [4] - HeYe Health is developing an integrated service system combining medical, pharmaceutical, and insurance services, aiming to alleviate outpatient medication payment pressures [4] Benefits for Industry Leaders - The new policies are expected to provide long-term benefits to leading retail pharmacies, enhancing their ability to manage outpatient prescriptions and increasing their market influence [6][7] - The industry is moving towards a new profit ecosystem that includes diversified services such as chronic disease management and medication guidance, which will improve revenue sources and customer loyalty [6][7]

Core Insights - The recent policy initiatives from nine government departments aim to promote high-quality development in the pharmaceutical retail industry, focusing on industry integration, prescription outflow, and commercial insurance [1][2][3] - The pharmaceutical retail market in China is expected to grow from CNY 2.41 trillion in 2020 to CNY 2.95 trillion by 2024, representing a 22.4% increase [2] - The industry is transitioning from traditional drug sales to comprehensive health services, enhancing community health support and resilience in the health security system [2][3] Industry Transformation - The policy encourages horizontal mergers and acquisitions among retail pharmaceutical companies to enhance efficiency and service quality [3][5] - Local governments are optimizing the business environment for retail pharmacies, including streamlining the application process for drug operation licenses [1] - Jiangxi Province has reported an increase in the retail pharmacy chain rate from 50.2% in 2024 to 60.3% in 2025, surpassing the national average [1] Company Responses - Yao Yi Tang is committed to responding to the new policies by enhancing its community health service capabilities and improving consumer access to quality healthcare [3] - Lao Bai Xing is exploring merger and acquisition opportunities while maintaining communication with potential targets to strengthen its alliance business [3] Industry Leaders' Benefits - The policy is expected to provide long-term benefits to leading retail pharmacies, enhancing their ability to manage outpatient prescriptions and increasing their market position [5][6] - The industry is entering a critical phase of structural transformation, characterized by store closures, increased concentration, and a restructured profit model [4][6] - The focus on diverse services such as chronic disease management and medication guidance will create a new profit ecosystem combining drugs, medical devices, and health management [4]

（文章来源：证券日报） 证券日报网讯 2月11日，第一医药在互动平台回答投资者提问时表示，为响应商务部等9部门《关于促 进药品零售行业高质量发展的意见》丰富健康服务、提升健康服务体验号召，回应上海市扩大服务消费 倡议，打破传统药店刻板印象、贴合年轻人主动健康消费与情绪价值需求，第一医药"氛子药局"由青年 团队主导设计，落子上海衡复风貌区，打造融合健康茶饮、微醺社交、药妆实验室等多个场景的复合型 健康空间，重构人货场，力求实现品牌从"药品销售"向"健康服务"的转型升级，为都市Z世代带来全新 健康消费体验，让老字号的专业底蕴与当代健康需求同频共振，为品牌注入持久活力。 ...

Core Viewpoint - The article highlights the proactive measures taken by the Yangyuan County Market Supervision Administration in Hebei Province to ensure drug safety during the upcoming Spring Festival by conducting a special inspection of the pharmaceutical market [1] Group 1: Inspection Focus - The inspection primarily targets retail pharmacies, focusing on commonly used medications during the festival, such as cold and fever remedies, health supplements, and emergency drugs [1] - Key areas of scrutiny include drug procurement channels, storage conditions, and expiration date management [1] Group 2: Compliance and Enforcement - The inspection emphasizes the enforcement of regulations regarding prescription drug sales and the presence of licensed pharmacists on duty [1] - Issues identified during the inspection, such as non-compliant record-keeping and untimely temperature and humidity documentation, were addressed on-site with immediate rectification orders [1] Group 3: Safety Measures and Future Actions - The inspection has contributed to the regulation of the local pharmaceutical market and the identification of potential drug safety hazards [1] - The Yangyuan County Market Supervision Administration plans to increase inspection efforts leading up to the festival, ensure follow-up on problem rectifications, and maintain open channels for complaints and reports [1]

Group 1 - The Beijing Municipal Market Supervision Administration will focus on addressing monopolistic behaviors in platform economies and will implement comprehensive measures to rectify "involution" competition in the accommodation and catering sectors by 2026 [1][2] - A nationwide live e-commerce monitoring platform is being accelerated to adapt to the challenges posed by new business models in live streaming e-commerce, aiming to create a data-driven and multi-governance monitoring system [2][3] - The administration will enhance the enforcement of regulations against counterfeit goods, false advertising, and predatory pricing, promoting a fair and competitive market environment [3] Group 2 - In 2025, the number of business entities in Beijing reached 2.8697 million, marking a year-on-year growth of 6.83%, with over 40% being technology-based enterprises [6] - The survival rate of enterprises in Beijing has remained above 75% for the past three years, indicating a robust business environment and high-quality development of business entities [6] - The Beijing Municipal Market Supervision Administration has introduced various reforms to improve the business environment, including the issuance of new local standards for business registration and the promotion of innovative regulatory practices [7]

Core Insights - Beijing's Market Supervision Administration will focus on addressing monopolistic behaviors in platform economy sectors, particularly in accommodation and catering industries, by implementing comprehensive regulations and monitoring systems by 2026 [1][2][7] Group 1: Regulatory Actions - The administration will conduct a thorough "health check" on key platform enterprises, particularly in the accommodation and catering sectors, to combat "involution" competition [2][7] - A negative list of eight types of behaviors will be established to regulate the platform economy, with a focus on enhancing compliance management [7] - The administration is accelerating the establishment of a national live e-commerce monitoring platform to address the challenges posed by new business models [2][7] Group 2: Consumer Protection and Rights - In 2025, the administration upgraded the management of single-purpose prepaid cards and introduced local standards for administrative mediation of consumer disputes [8] - Plans for 2026 include the establishment of 100 consumer rights protection service stations and 50 consumer education bases to enhance consumer protection [8] - The administration will maintain a high-pressure stance against "professional store closers" and promote third-party platforms for consumer compensation [8] Group 3: Business Environment and Growth - By the end of 2025, the number of business entities in Beijing reached 2.8697 million, a year-on-year increase of 6.83%, with over 40% being technology-based enterprises [11] - The survival rate of enterprises over the past three years has exceeded 75%, indicating a robust business environment [11] - The administration has implemented various innovative measures to improve the business environment, including the launch of a series of local standards for business registration services [11][12] Group 4: Food Safety and Quality Control - In 2026, Beijing will enhance its food safety traceability and risk warning systems, focusing on online dining safety and implementing special rectification actions [9][10] - The administration has introduced a new supply model for school meals, integrating digital platforms for food processing oversight [10] Group 5: Monitoring and Compliance - The administration has improved its monitoring capabilities, covering over 8,000 key live streaming rooms and releasing ten measures to regulate unreasonable business practices in live commerce [7] - A comprehensive regulatory framework is being developed to ensure fair competition and address issues such as counterfeit goods and false advertising [7][12]

Market Overview - The A-share market experienced a correction today, with the Shanghai Composite Index falling by 2.48% to close at 4015.75 points, and the Shenzhen Component Index dropping by 2.69% to 13824.35 points. Most sectors declined, with the precious metals sector nearly hitting the limit down, while only the food and beverage industry saw a slight increase. The market is currently in a deleveraging phase, indicating potential for further pullback, but as valuation pressures ease, new investment opportunities may gradually emerge [1] Solar Industry - The solar sector showed strong performance in the morning, with the solar industry index rising over 2% at one point, although it later retreated but still outperformed the broader market. Tesla CEO Elon Musk's recent proposal for "space solar" has opened new imaginative possibilities for the industry. Additionally, the Ministry of Industry and Information Technology held a meeting to address "involution" in the solar industry, emphasizing mergers and acquisitions and standard-setting to eliminate excessive competition. With the implementation of "anti-involution" policies and a surge in energy demand, the solar industry is expected to enter a recovery cycle characterized by simultaneous growth in volume and profit. For investors optimistic about energy transition and industry recovery, this may be an opportune time to consider the Guotai Solar ETF (159864) [1] Pharmaceutical and Biotech Sector - The pharmaceutical and biotech sector has demonstrated strong capital attraction recently, with market sentiment significantly improving. The investment rationale for the sector is primarily supported by "innovation realization" and "valuation recovery." Domestic innovative drugs are entering a phase of commercial explosion and internationalization. Furthermore, supportive policies from the Ministry of Commerce and other departments have been released to promote mergers and high-quality development in the pharmaceutical retail industry. The Biopharmaceutical ETF (512290) closely tracks the CSI Biopharmaceutical Index, encompassing both the growth potential of innovative drugs and the stability of medical device performance. This ETF's focus on leading companies and comprehensive industry coverage makes it a representative of core assets in China's biopharmaceutical industry, warranting investor attention [2] Electric Grid Sector - The Electric Grid ETF (561380) rose by 1.06% today. In terms of domestic demand, reports indicate that transformer factories in Guangdong and Jiangsu are operating at full capacity, with some orders for data center business extending to 2027. During the 14th Five-Year Plan, the State Grid Corporation's fixed asset investment is expected to reach 4 trillion yuan, a 40% increase compared to the previous plan. Additionally, the ongoing global energy transition is driving demand for new energy integration. The sector benefits from a combination of "order explosion, increased domestic investment, and overseas demand potential," supported by strong performance from leading grid equipment companies, making it a sector to watch for investors [2] Precious Metals Sector - The precious metals sector continued to experience significant adjustments today. Concerns over tightening U.S. monetary policy have heightened market sensitivity to negative news, leading to sharp corrections as a result of emotional and trading structure responses. However, long-term expectations regarding potential interest rate cuts by the Federal Reserve have not fundamentally changed, and geopolitical risks continue to provide long-term support for gold prices. In the short term, after the release of concentrated selling pressure, there may be a rebound and recovery window. In the medium to long term, the logic supporting gold prices remains intact, driven by the "Federal Reserve's rate cut cycle, increasing overseas uncertainties, and the global trend of de-dollarization." Investors are encouraged to monitor investment opportunities in the Guotai Gold ETF (518800) and Gold Stock ETF (517400) [3]